Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

 To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin
 alone in patients with heterozygous familial hypercholesterolemia
For additional information please call: 1-800-718-1021
Inclusion Criteria:

 -  Diagnosis of Heterozygous Familial Hypercholesterolemia

 -  At least 18 years of age

 Exclusion Criteria:

 -  Women who are pregnant or lactating, or planning to become pregnant.

 -  Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor)
 therapy other than atorvastatin or other concomitant therapy with known lipid altering
 effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)

 -  Subjects taking any drugs known to be associated with an increased risk of myositis in
 combination with HMG-CoA reductase inhibitors

 -  Subjects with any other medical condition or laboratory abnormality which could affect
 subject safety, preclude evaluation of response, or render unlikely that the subject
 would complete the study